MMI-0100 - ≥99% , CAS No.1039342-24-9

CAS: 1039342-24-9 Cat. No.: M650115 Formula: C₉₈H₁₇₁N₃₇O₂₆ Molecular Weight: 2283.64 PubChem CID: 127043567

GRADE & PURITY ≥99%

Storage

Protected from light,Argon charged,Desiccated,Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II ( MK2 ). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease.

In Vitro

Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner.. MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone. MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100. MMI-0100 does not induce EC apoptosis at any dose. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: human endothelial cell (EC) and smooth muscle cell (SMC) Concentration: 0.25, 0.5, and 1 mM Incubation Time: 24 hours Result: Slightly increased cell proliferation in both cell types compared to control cells.

In Vivo

MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 12-week-old C57Bl/6 wild type mice (intimal hyperplasia) Dosage: 100 μM Administration: vein graft, 28 days Result: Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.

Form:Solid

Specifications

Specifications & Purity

≥99%

Biochemical and Physiological Mechanisms

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II ( MK2 ). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-010

Storage

Protected from light,Argon charged,Desiccated,Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Purity

≥99%

Names and Identifiers

Isomeric SMILES

C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N

PubChem CID

127043567

Molecular Weight

2283.64

Mechanisms of Action

Chemical and Physical Properties

• Solubility: H2O : 100 mg/mL (43.79 mM; Need ultrasonic)